A Year on the Urticaria Ladder Before Anyone Asked About His Bones
A partial response to a urticaria drug kept his real diagnosis hidden for a year. Now that it's named, the argument is whether that partial response still means something.
For just over a year, treatment for what three different clinicians called refractory chronic spontaneous urticaria did nothing to explain the rest of what was happening to Walter S., a 58-year-old retired shipping-yard foreman: low-grade fevers every few weeks, and a deep, aching pain in both shins and his pelvis he had attributed to “old injuries acting up” from decades of yard work. The urticaria itself — a persistent, minimally itchy rash of raised red wheals that never fully cleared — was escalated first through standard-dose antihistamines, then to four times the standard dose per updosing guidelines, and finally to omalizumab once the antihistamine ladder plateaued. The omalizumab produced a real, if partial, benefit — his flare-free days per month roughly doubled, though the rash never fully resolved and new lesions continued to appear most weeks.
A rheumatology referral, prompted only after a routine complete metabolic panel incidentally flagged an elevated total protein, found a monoclonal IgM gammopathy on serum protein electrophoresis — the finding that, combined with his chronic urticarial rash, fever, bone pain, and a CRP that has run persistently elevated throughout the year he was being treated for urticaria alone, meets the Strasbourg diagnostic criteria for Schnitzler syndrome. A skin biopsy taken during this same workup showed a neutrophilic dermal infiltrate rather than the more typical mast-cell and eosinophil-predominant pattern of ordinary chronic urticaria — a real, specific histologic difference that had simply never been looked for while the diagnosis in front of everyone was CSU. The rash that brought him in a year ago turns out to be the least specific feature of what he has, and the two features that were specific — the bone pain he put down to the shipping yard, the fevers nobody connected to anything — were in the chart the whole time. His next omalizumab dose is due Thursday, which is when someone has to decide whether a drug aimed at the least specific feature of his disease is still worth giving.
What a partial response was actually responding to
Schnitzler syndrome isn't a variant of urticaria — it's a distinct autoinflammatory disease that happens to include urticaria as one feature. De Koning's Schnitzler series and Krause and colleagues' anakinra work describe near-universal, often dramatic responses to IL-1 blockade in genuinely diagnosed patients. Now that we know what this actually is, I'd move to anakinra as the disease-specific therapy rather than continuing to manage him along a treatment ladder built for a different disease.
I don't disagree with the diagnosis, but I'd point out that his flare-free days roughly doubled on omalizumab — that's a real, measured clinical response, not a placebo effect I'm imagining after a year of watching him closely. That suggests some genuine IgE or mast-cell contribution to his urticaria, even inside a disease we now know is fundamentally IL-1-driven.
I'm not arguing against starting anakinra. I'm arguing against automatically stopping a therapy that's been doing real, if partial, work, just because a new diagnosis reframes what else is going on.
I think the disagreement is actually about which symptom omalizumab's partial response should be judged against. His fevers, bone pain, and CRP — the features that actually define Schnitzler syndrome — never responded to omalizumab at all. Those are the outcomes anakinra is expected to control, and they're the right measuring stick for this decision, not the rash alone.
I'd start anakinra now and track fever frequency, bone pain, and CRP specifically. If those normalize and his skin also clears, omalizumab's partial effect becomes moot rather than something we have to argue about. If his skin doesn't fully clear even once the systemic disease is controlled, that's exactly when the Allergist's point about a possible independent IgE component becomes the stronger argument for keeping it.
Anakinra was started with a defined tracking plan for fever frequency, bone pain, and CRP, and omalizumab was continued rather than stopped outright — the team's explicit way of letting the systemic markers, not the rash alone, determine whether the partial urticaria response omalizumab had been providing turns out to still matter.
Not agreed in advance: what happens if anakinra fully controls the systemic features but his skin only partially clears. The Allergist would take that as confirmation of a real independent IgE component worth continuing to treat; the Rheumatologist would want a longer anakinra trial and possible dose adjustment first, on the view that skin clearance in Schnitzler syndrome can lag behind systemic control even when the same drug is ultimately responsible for both. Both agreed to revisit the question together once the tracked markers are actually in hand, rather than predict the outcome tonight.